2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144701
    SABA1 690681-65-3 99.15%
    SABA1 possesses antibacterial properties against Pseudomonas aeruginosa and Escherichia coli, with an IC50 of 4.0 µM against E. coli ACC.
    SABA1
  • HY-145107
    HPK1-IN-19 2227609-33-6 98.04%
    HPK1-IN-19 (Compound I-47) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
    HPK1-IN-19
  • HY-145351
    BAY 1003803 1152781-51-5 99.85%
    BAY 1003803 is a glucocorticoid receptor agonist for the topical research of psoriasis or severe atopic dermatitis.
    BAY 1003803
  • HY-145466
    (Rac)-EVT-401 99.78%
    (Rac)-EVT-401 (HY-145466) is the racemate of EVT-401 (HY-178230). (Rac)-EVT-401 is a P2X7 receptor antagonist that can be used in research related to rheumatoid arthritis.
    (Rac)-EVT-401
  • HY-14546A
    Aripiprazole monohydrate 851220-85-4 99.83%
    Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19.
    Aripiprazole monohydrate
  • HY-145721
    Mongersen 1443994-46-4
    Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen can attenuate Crohn's disease-like experimental colitis in mice.
    Mongersen
  • HY-145726
    ISIS 104838 250755-32-9
    ISIS 104838 is an antisense oligonucleotide targeting TNF-α. ISIS 104838 specifically binds to human TNF-α mRNA via Watson-Crick base pairing to form a DNA:RNA hybrid duplex, thereby recruiting the ubiquitously expressed intracellular enzyme RNase H to degrade the target mRNA and inhibit TNF-α protein synthesis at the transcriptional level. ISIS 104838 induces moderate, self-limiting thrombocytopenia in cynomolgus monkeys. ISIS 104838 can be used for the study of inflammatory diseases.
    ISIS 104838
  • HY-146577
    Keap1-Nrf2-IN-7 2769963-42-8 99.82%
    Keap1-Nrf2-IN-7 (compound 7v) is a potent Keap1-Nrf2 PPI (Keap1-Nrf2 protein−protein interaction) inhibitor with an IC50 of 0.45 µM.
    Keap1-Nrf2-IN-7
  • HY-146811
    HSGN-94 2570797-85-0 98.80%
    HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model.
    HSGN-94
  • HY-147108
    Mitochondria degrader-1 2241669-05-4
    Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease.
    Mitochondria degrader-1
  • HY-147128
    PY109 2378039-23-5 99.15%
    PY109 is an orally active and highly selective aryl hydrocarbon receptor (AHR) agonist. PY109's EC50 values in human-derived HepG2 and mouse Hepa-1c1c7 cells are 1.2 nM and 1.4 nM respectively. PY109 significantly upregulates the expression of CYP1A1 and IL-22, and inhibits the expression of IL-17A. PY109 significantly improves colitis in mice. PY109 can be used for research on colitis.
    PY109
  • HY-147249
    CFTR corrector 8 1918142-35-4
    CFTR corrector 8 is a potent CFTR modulator. CFTR can be used in the research of cystic fibrosis.
    CFTR corrector 8
  • HY-147830
    PDE4B-IN-3 2819779-01-4 99.37%
    PDE4B-IN-3 is a potent PDE4B inhibitor with an IC50 of 0.94 μM. PDE4B-IN-3 has anti-inflammatory activities.
    PDE4B-IN-3
  • HY-148492
    Mrgx2 antagonist-2 2767111-67-9 98%
    Mrgx2 antagonist-2 (Example 132) is a Mrgx2 antagonist with a pIC50 of 8.6. Mrgx2 antagonist-2 can be used in the research of MrgX2 -mediated diseases or disorders.
    Mrgx2 antagonist-2
  • HY-148656
    PNB-001 1528760-09-9 99.65%
    PNB-001 is an orally active CCK2 selective ligand and antagonist. PNB-001 has anti-inflammatory and analgesic activities.
    PNB-001
  • HY-148940
    Docosahexaenoyl glycerol 140670-40-2 ≥99.0%
    Docosahexaenoyl glycerol is an analog of endocannabinoid, which stimulates the glucose uptake and exhibits anti-inflammatory efficacy.
    Docosahexaenoyl glycerol
  • HY-149136
    MORF-627 2412688-16-3 98%
    MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety.
    MORF-627
  • HY-149258
    KWCN-41 2913223-17-1 99.83%
    KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis. KWCN-41 also has anti-inflammatory effects.
    KWCN-41
  • HY-149282
    IL-1β-IN-2 2242896-76-8 99.38%
    IL-1β-IN-2, cannabigerol derivative, is a potent IL-1β inhibitor. IL-1β-IN-2 has anti-inflammatory and pain-resolving properties.
    IL-1β-IN-2
  • HY-14956S
    Nemonoxacin-d3 99.93%
    Nemonoxacin-d3 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
    Nemonoxacin-d3
Cat. No. Product Name / Synonyms Application Reactivity